NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Intellia Therapeutics, Inc. (NTLA) Stock Analysis

Intellia Therapeutics, Inc. (NTLA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NTLA

$12.74

+$0.06 (+0.47%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NTLA with… →

NTLA Key Statistics

As of Sep 4, 2026
Trading
Open
$12.59
Previous Close
$12.68
Day's Range
12.52–12.96
52-Week Range
7.95–28.25
Volume
2.79M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.82
Valuation
Market Cap
$1.79B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
30.00
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.34
Financials (FY)
Revenue (FY)
$67.67M+16.92%
Net Income (FY)
−$412.69M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
140.13M
1-Year Return
+9.64%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
4.63M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NTLA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+41.71%
2025−22.90%
2024−61.76%
2023−12.61%
2022−70.49%
2021+117.35%
2020+270.82%
2019+7.47%
2018−28.98%
2017+46.61%
2016 (partial year)−32.32%

As of September 4, 2026.

NTLA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$67.67M−$412.69M−609.9%
2024$57.88M−$519.02M−896.8%
2023$36.28M−$481.19M−1326.5%
2022$52.12M−$474.19M−909.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$67.67M—−$440.99M−$412.69M−609.9%
2024$57.88M—−$534.26M−$519.02M−896.8%
2023$36.28M—−$515.29M−$481.19M−1326.5%
2022$52.12M—−$458.16M−$474.19M−909.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NTLA Valuation vs Biotechnology Median

Median of 656 stocks
MetricNTLABiotechnology medianvs median
P/S ratio30.0015.2697% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Intellia Therapeutics, Inc. (NTLA) is capitalised at $1.79B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 377.

The most recent close on file for NTLA is $12.74, dated September 4, 2026. That is +$0.06 (+0.47%) against the previous close. Over the past 52 weeks the price has ranged from $7.95 to $28.25. The latest close sits 60.25% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $67.67M. Against the prior fiscal year total of $57.88M, that is a change of +16.92%. The same year closed with a net loss of $412.69M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −3.34.

Across the 4 fiscal years on file, revenue moves from $52.12M in 2022 to $67.67M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 30. On price-to-sales that is 96.55% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +9.64%. Measured over 10 years, that is −4.32% a year compounded. The reported beta is 1.82. Annualized volatility over the trailing 10 years is 78.55%.

Growth & Income

No dividend is on file for NTLA.

The strongest complete calendar year on file is 2020 at +270.82%; the weakest is 2022 at −70.49%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is +41.71% year to date.

Peer Comparison

Intellia Therapeutics, Inc. (NTLA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Intellia Therapeutics, Inc. NTLA $1.79B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Intellia Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Visit website →